Advances in Pharmacogenetics in Primary Care - Mainpro+
This eCME is directed to primary care clinicians (family physicians, nurse practitioners and pharmacists) in the therapeutic area of pharmacogenetic testing and personalized medicine. This one-hour program will be accredited through the CFPC and CCCEP.
Pharmacogenomics (PGx) focuses on understanding how genes affect individual responses to medications, i.e., the relationship between drug responses and genetic variants. PGx testing provides objective data about specific aspects of an individual’s genetic makeup that may predict an individual’s response to medications. For example, the liver enzyme CYP2D6 is involved in metabolizing a quarter of all prescriptions and exists in more than 160 known variants. Some variants can negatively impact how particular drugs are metabolized by individuals who carry the variants.
This Self-Learning program has been certified by the College of Family Physicians of Canada for up to 1.5Mainpro+ Credit(s). Cert+ Program ID#: 189185
Moe Abdallah, BSc., BSc. Pharm., R.Ph.
John Axler, MD, CCFP, FCFP
Jahed Khoshnood, BSc, PharmD, RPh
Daniel Mueller, MD, PhD
John Papastergiou, BSc Phm, RPh
Sol Stern, MD, MCFP
Deanna Telner, MD, CCFP
Upon completion of the program, participants will be able to:
- Summarize the benefits and challenges of pharmacogenetic testing;
- Identify key variables that should be considered for precision prescribing and why precision prescribing should include more than pharmacogenetics;
- Explain how knowledge of an individual’s genetic variants may impact choice and/or dosage of medications;
- Identify three scenarios in which pharmacogenetic testing may impact treatment choices;
- Discuss how you might counsel patients about pharmacogenetic testing and the importance of proper interpretation of the results by a healthcare provider.